A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Eli Lilly and Company
Children's Oncology Group
Seattle Children's Hospital
Milton S. Hershey Medical Center
Institut Curie
The Hospital for Sick Children
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
The University of Texas Health Science Center, Houston
City of Hope Medical Center
The University of Texas Health Science Center, Houston
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Celgene
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
University of Iowa
Children's Oncology Group
Children's Cancer Hospital Egypt 57357
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
University of Colorado, Denver
Wake Forest University Health Sciences
University of Iowa
Wake Forest University Health Sciences
Pediatric Brain Tumor Consortium
Children's Cancer Hospital Egypt 57357
National Cancer Institute (NCI)
Oncurious NV
University of Iowa
Novartis
M.D. Anderson Cancer Center
Ann & Robert H Lurie Children's Hospital of Chicago
Lumos Pharma
Emory University